Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Why the study?
Does lixisenatide reduce major cardiovascular events in patients with type 2 diabetes and a recent acute coronary syndrome?
Population
Patients with type 2 diabetes and a recent acute coronary syndrome
Comparison
Lixisenatide added to usual care vs Usual care
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Lixisenatide adds no cardiovascular protection after acute coronary syndrome in type 2 diabetes; confirms neutral primary outcome for this GLP-1 receptor agonist.
Structured PICO
Does lixisenatide reduce major cardiovascular events in patients with type 2 diabetes and a recent acute coronary syndrome?
P
Population
Patients with type 2 diabetes and a recent acute coronary syndrome
I
Intervention
Lixisenatide added to usual care
C
Comparator
Usual care
O
Outcome
Rate of major cardiovascular eventscomposite
In patients with type 2 diabetes and recent acute coronary syndrome, adding lixisenatide to usual care does not significantly reduce major cardiovascular events.
Cite This Study
Pfeffer et al. (2015) studied this question.